KLOW is a commercially formulated peptide blend combining four synthetic peptides into a single lyophilized vial (80 mg total). It is available from multiple peptide vendors as "KLOW 80" or "KLOW Blend." The formulation consists of:
| Component | Amount | Source / Class | Proposed Role in Blend |
|---|---|---|---|
| GHK-Cu (Copper Tripeptide-1) | 50 mg | Naturally occurring copper-binding tripeptide (Gly-His-Lys + Cu²+) | Collagen/elastin synthesis, ECM remodeling, gene expression modulation |
| KPV (Lys-Pro-Val) | 10 mg | C-terminal tripeptide of alpha-MSH | NF-kB inhibition, anti-inflammatory signaling, intestinal barrier support |
| BPC-157 (Body Protection Compound) | 10 mg | Synthetic 15-AA gastric peptide fragment | Angiogenesis, nitric oxide modulation, connective tissue repair |
| TB-500 (Thymosin Beta-4 Fragment) | 10 mg | Synthetic 7-AA fragment (Ac-LKKTETQ) of thymosin beta-4 | Actin sequestration, cell migration, tissue remodeling |
The rationale behind KLOW is that combining peptides targeting different but complementary biological pathways (anti-inflammatory, pro-angiogenic, ECM remodeling, and cell migration) might produce synergistic regenerative effects greater than any single peptide alone.
Critical evidence context: While this rationale is scientifically plausible, it is entirely theoretical. There are zero published studies examining these four peptides in combination, in any model system. The "synergy" claim has never been tested. Furthermore, none of the four individual components has published human clinical trials as isolated therapeutics. The evidence base for each component is primarily preclinical (in vitro and animal models). Two components (BPC-157 and TB-500) are classified by the FDA as Category 2 bulk drug substances with significant safety concerns, prohibited for compounding.
| Weeks | Dosage | Syringe units (U-100) |
|---|---|---|
| Weeks 1–2 | 2 mg | 7.5 units0.07 mL |
| Weeks 3–4 | 4 mg | 15 units0.15 mL |
| Weeks 5–8 | 6 mg | 22.5 units0.22 mL |
| Weeks 9–12 | 4 mg | 15 units0.15 mL |
FrequencyOnce daily, subcutaneous.
For review — no human dosing exists for this blend. Neither KLOW nor a comparable four-component blend has been through a human trial, so there is no established amount, ratio or frequency; the rows in the chart follow a circulated research protocol. The concentration strip above the chart is calculated from the vial and water volume and is correct.
Unverified — no study of the blend establishes a frequency.
The 80 mg strength is the composition documented in the table further down this page — GHK-Cu 50 mg with KPV, BPC-157 and TB-500 at 10 mg each — so the amounts charted here split in that same fixed proportion, and a 4 mg daily amount delivers about 2.5 mg of GHK-Cu and 0.5 mg of each of the other three. No human trial of this combination or of any comparable four-component blend exists, so the schedule is a circulated protocol and is flagged for review; the final row steps back down from 6 mg to 4 mg as a maintenance phase, which is the protocol's structure rather than a finding. Made up with 3 mL the vial is about 26.7 mg/mL, giving 7.5, 15, 22.5 and 15 units across the four rows — every one inside a single 50-unit syringe. Because four peptides are fixed in one vial, none of them can be adjusted independently of the others.
What this evidence establishes. No human dosing exists for the KLOW blend. Neither the combination nor a comparable four-component blend has been through a human trial, so there is no established dose, ratio or frequency for it. The component amounts per vial are documented in the composition table further down this page; those are what the vial contains, not a studied dose. Because the components are fixed in one vial, they cannot be titrated independently the way the individual compounds were studied.
For educational and laboratory research purposes only. It does not provide medical advice, dosing recommendations, or instructions for human or veterinary use. Syringe units assume a U-100 syringe, on which 1 mL is 100 units and a 50-unit syringe holds 0.5 mL.
Each component targets a distinct biological pathway. The following mechanisms are derived from preclinical research on the individual peptides, not on the KLOW combination:
Copper-binding tripeptide that stimulates collagen synthesis, attracts immune cells to injury sites, and modulates expression of 4,000+ genes involved in tissue repair (Pickart et al.)
Suppresses inflammatory signaling via PepT1-mediated intracellular uptake. Reduces TNF-alpha, IL-6, and IL-1beta without melanocortin receptor activation (Dalmasso et al., 2008)
Modulates nitric oxide system, promotes blood vessel formation, and protects gastrointestinal mucosa. FDA Category 2 substance. Zero human trials. (Sikiric et al.)
Synthetic fragment of thymosin beta-4 that sequesters G-actin and promotes cell migration to injury sites. FDA Category 2. WADA prohibited. Zero human trials. (Goldstein et al.)
No published research examines these four peptides together. Potential interactions (synergistic or antagonistic) between components are unknown and untested.
Long-term stability of four peptides co-formulated in a single vial has not been validated in published research. Peptide-peptide interactions during storage are unstudied.
There is no safety data on the KLOW combination. The following is derived from the individual component literature, which is itself overwhelmingly preclinical. Interactions between the four components are completely unknown.
| Concern | Risk Level | Rationale |
|---|---|---|
| Active cancer or malignancy | HIGH | TB-500 promotes angiogenesis and cell migration. BPC-157 promotes angiogenesis. Both mechanisms could theoretically support tumor growth and vascularization. |
| FDA Category 2 classification (BPC-157, TB-500) | HIGH (regulatory) | Two of four components are classified by FDA as having significant safety concerns and are prohibited from compounding for human use. |
| Pregnancy / breastfeeding | HIGH | No reproductive safety data exists for any component or the combination. Standard exclusion for unstudied compounds. |
| Drug-drug interactions | UNKNOWN | Zero interaction studies exist for any pair or combination of these four peptides. Pharmacokinetic and pharmacodynamic interactions are completely uncharacterized. |
| Peptide-peptide interactions in formulation | UNKNOWN | Stability, degradation kinetics, and potential chemical interactions between four co-formulated peptides in a single vial have not been validated. |
| Autoimmune conditions | MODERATE (theoretical) | TB-500 has immune-modulating properties. KPV suppresses NF-kB. Combined effects on autoimmune disease are unknown. |
| Anticoagulant therapy | MODERATE (theoretical) | TB-500's angiogenic and platelet-related activity may interact with anticoagulant therapy. Not studied. |
| Human safety data (individual components) | ABSENT | Zero published human clinical trials for BPC-157, TB-500, or KPV as isolated therapeutic compounds. GHK-Cu has topical cosmetic data but no injectable human trial data. |
| Human safety data (combination) | ABSENT | Zero published studies of any kind on the four-peptide KLOW combination in any model system. |
| Quality control / manufacturing | VARIABLE | Purity, sterility, and accurate dosing vary by vendor. Source from reputable suppliers with third-party testing and Certificates of Analysis. |
FDA: No component of the KLOW blend is FDA-approved for therapeutic use. BPC-157 and TB-500 are specifically classified as FDA Category 2 bulk drug substances, meaning they have been identified as presenting significant safety risks and are prohibited from being compounded for human use.
WADA: TB-500 is classified under S0 (Non-Approved Substances) on the WADA Prohibited List. Banned at all times, in and out of competition.
DEA: None of the components are DEA-scheduled substances.
Availability: KLOW is available from multiple peptide suppliers and is used in integrative medicine and peptide therapy practices.
Key distinction: A peptide blend is not inherently more effective than its individual components. "Synergy" is a specific pharmacological claim that requires experimental validation. No published data supports the claim that combining GHK-Cu, KPV, BPC-157, and TB-500 produces effects greater than any individual component. The blend format may simplify administration logistics but does not create new evidence.
Answer these questions to evaluate your understanding of the KLOW blend's evidence base, regulatory status, and component risks.
This profile is for educational and research purposes only. It is not medical advice, and nothing on it is a protocol, a recommendation, or an instruction for use in a person or an animal.
Athena Peptides Education does not prescribe, sell, or recommend any compound. Compounds discussed here are for laboratory research only and are not for human consumption. Always consult a qualified physician before making any decision about your health.